Deep Dives/Pharma Packaging/GSM Foils Ltd

Deep Dive

₹258 Cr revenue in just 2 years — but where's the cash?

This pharma foil converter nearly doubled revenue every year since listing. But operating cash flow has been negative every single year — ₹94 Cr locked in receivables.

KnowYourSME Research

May 2026 · 9 min read

₹258 Cr

Revenue FY26

₹19.8 Cr

PAT FY26

39.9%

ROCE

(₹36.8 Cr)

Operating CF

1Executive Summary & Investment Thesis

GSM Foils is a fast-growing aluminium foil converter for the Indian pharmaceutical industry, operating as a Tier-2/3 processor — buying aluminium coils from Hindalco, then coating, laminating, printing and slitting them into pharma-grade blister foils (~35%) and strip foils (~65%). Revenue has exploded from ₹40.8 Cr (FY24) to ₹133.8 Cr (FY25) to ₹258.2 Cr (FY26) — a near-doubling every year. PAT followed: ₹1.37 Cr → ₹9.65 Cr → ₹19.84 Cr with improving margins (EBITDA 11.5%, PAT 7.7% in FY26). ROCE hit 39.9%. However, operating cash flow has been negative every single year since inception — (₹13 Cr) in FY24, (₹17.7 Cr) in FY25, and (₹36.8 Cr) in FY26. Trade receivables exploded from ₹7.2 Cr to ₹94.3 Cr (13x increase on 6.3x revenue growth). The company operates on a PO-to-PO model with no long-term contracts, no formal order book, and no entry barriers. FY27 target: ₹400-450 Cr.

6/10

High Growth, High Risk — Cash Flow Is the Achilles Heel

The revenue growth is impressive and pharma packaging is defensive. But persistently negative OCF, exploding receivables, zero entry barriers, and PO-to-PO model make this high-risk. Suitable only for investors who understand working capital cycles and can tolerate the risk that growth requires ever-expanding debt.

Bull Case

+Revenue nearly doubling every year for three consecutive years with FY27 guidance of ₹400-450 Cr
+EBITDA margins stable at 11-12% with ROCE of 39.9% — highly efficient asset-light model
+Pharma packaging is defensive and non-cyclical with anti-dumping duty protection
+Asset-light — Ahmedabad capex was just ₹5.5 Cr for ₹300+ Cr capacity
+100+ pharma clients with zero concentration risk and zero bad debts in 5 years
+Main board listing aspiration in 1.5-2 years

Bear Case

−Operating cash flow negative every year since inception — profits on paper but not in the bank
−No entry barriers — management explicitly admits it. Commodity conversion business
−Short-term borrowings surged 10x to ₹44.4 Cr to fund receivables-heavy model
−PO-to-PO model with no long-term contracts — zero revenue visibility
−Unhedged aluminium price exposure — no formal hedging strategy
−Promoter share sale in April 2026 raises optics concerns despite voluntary lock-in

2Business & Management Architecture

The Journey

GSM Foils was incorporated in September 2023 in Mumbai — one of the youngest companies to list on the SME platform. Founded by Sagar Girish Bhanushali (a qualified Chartered Accountant) and Mohansingh Laxmansingh Parmar, the company entered aluminium foil conversion for pharmaceutical packaging. The model is straightforward: buy aluminium coils from Hindalco (100% cash), convert through coating, lamination, printing and slitting into pharma-grade foils, and sell to 100+ pharmaceutical companies on 45-70 day credit. Two product lines — blister foils (~35%) and strip pharma foils (~65%) — serve India's massive generic pharmaceutical industry. Listed on NSE Emerge on May 31, 2024 at ₹32/share with a ₹11 Cr IPO, the company scaled from ₹40.8 Cr to ₹258.2 Cr in FY26. The Vasai facility runs at 85-87% utilization, and a new Ahmedabad plant became operational in December 2025. Management's playbook: scale aggressively in a fragmented market where working capital management is the real competitive advantage.

Revenue Segments

~65%

Aluminium Strip Pharma Foils

Pre-printed and plain aluminium foils for strip packaging of pharma tablets and capsules.

~35%

Blister Foils

Aluminium foils with heat-seal lacquer coating for blister packing of pharmaceutical products.

Key Management

Mohansingh Laxmansingh Parmar · Managing Director

Co-founder. Holds 38.27% stake. Leads business development and operations.

Sagar Girish Bhanushali · WTD & CFO

Co-founder. Holds 34.87% stake. Qualified CA. Primary concall spokesperson. Manages finance, strategy, and IR.

Board of Directors · 5-member board

5 directors including independent directors per SEBI mandate. 31 permanent employees as of FY25.

Promoter

73.14%

Public

26.86%

Management flags: Two-promoter company with 73.14% combined holding. Only 31 permanent employees for ₹258 Cr revenue. Bhanushali (CA) is articulate on concalls. One promoter sold shares in April 2026, followed by 18-month voluntary lock-in. No independent professional management. Company incorporated Sep 2023 — extremely young. Key-person risk is high.

3Industry & Market Dynamics

Industry Overview

India's pharmaceutical packaging market valued at ~$15 billion growing at 8-10% annually. India produces 20% of global generic drugs. Aluminium foil conversion is highly fragmented with minimal entry barriers. Anti-dumping duties on Chinese/Thai imports protect domestic converters. Competitive advantage lies in working capital management and client relationships, not technology. Hindalco is the dominant raw material supplier with monthly price letters.

Competitive Landscape

Competes against backward-integrated players (PG Foils, MMP Industries) who own rolling mills and have structural cost advantages. Synthiko Foils is a closer peer as a pure converter. GSM differentiates on growth rate and asset efficiency (39.9% ROCE) but lacks vertical integration moat. Numerous unlisted regional converters compete in this fragmented space.

Peer Context

Listed peers include PG Foils (backward-integrated, rolling mill owner) and MMP Industries/MMP Foil (also backward-integrated). Both have structural advantages from owning rolling mills. Synthiko Foils is a closer peer as a pure converter. GSM differentiates on growth rate and asset efficiency (39.9% ROCE) but lacks vertical integration moat. Numerous unlisted competitors in this fragmented space.

4IPO & Capital Structure

IPO Details

Issue Size

₹11.01 Cr (34.4 lakh shares at ₹32/share)

Price Band

₹32 per share

Platform

NSE Emerge (SME)

Listing Date

May 31, 2024

Subscription

IPO oversubscribed

Objects of Issue

1.Working capital requirements for business operations

2.General corporate purposes

3.Issue-related expenses

Capital Structure

IPO raised ₹11 Cr at ₹32/share. Rights issue of ~₹23 Cr completed. Short-term borrowings surged from ₹4.5 Cr to ₹44.4 Cr (10x in 2 years). D/E at 0.6-0.7x. Banking with DBS, Tata Capital, ICICI. Every rupee of growth requires external funding because operating cash flow is negative.

IPO Promise Tracker

Has management delivered on IPO promises?

Not Started

Fund working capital for expansion

IPO proceeds fully consumed. Additional ₹23 Cr rights issue and ₹44.4 Cr borrowings deployed.

Not Started

Scale revenue through capacity expansion

Revenue scaled 6.3x from ₹40.8 Cr to ₹258.2 Cr in 2 years.

Not Started

Establish Ahmedabad facility

17,000 sq ft facility operational from Dec 2025. ₹5.5 Cr capex. 25-30% utilization.

Not Started

Sustainable EBITDA margins of 11-12%

EBITDA margins stable at 11.2-11.9% across quarters.

Not Started

Working capital cycle to 50-60 days

Working capital days at 60-70 days. Receivables growing faster than revenue.

Not Started

Backward integration into Lamitube

Repeatedly pushed back. Now 6-8 months from decision.

5Operational Performance & Growth

Operations & Capacity

Two manufacturing facilities: 1. Vasai, Maharashtra (15,000 sq ft, leased): ~10,000 MT/year capacity. Utilization at 85-87%. Revenue potential ₹28-30 Cr/month at full capacity. ISO 9001:2015 and CGMP certified. 2. Ahmedabad, Gujarat (17,000 sq ft, leased): Operational from Dec 2025. Capex ₹5.5 Cr. Additional 10,000 MT/year. Currently at 25-30% utilization. Targeting full capacity by FY27 end. Combined capacity: ~20,000 MT/year, supporting ₹55-60 Cr/month revenue at full utilization (₹650-700 Cr annualized). Process: buy aluminium coils from Hindalco (100% cash), convert through coating → lamination → printing → slitting, sell to pharma on 45-70 day credit.

Order Book & Pipeline

No formal order book exists. PO-to-PO model with no long-term contracts. Monthly run-rate in Q4 FY26 was ~₹27 Cr. Management expects highest-ever monthly sales in May 2026. FY27 target of ₹400-450 Cr implies ₹33-37 Cr monthly run-rate. Revenue visibility effectively limited to current month.

Key Milestones

2023-09

GSM Foils Limited incorporated in Mumbai, Maharashtra

2024-05

Listed on NSE Emerge at ₹32/share, raising ₹11 Cr

2025-03

FY25 revenue of ₹133.8 Cr — 3.3x growth from FY24

2025-08

Rights issue of ~₹23 Cr completed for working capital

2025-12

Ahmedabad plant (17,000 sq ft) becomes operational — ₹5.5 Cr capex

2026-03

FY26 revenue of ₹258.2 Cr — 93% YoY growth

2026-04

Monthly sales ₹27 Cr (+67% YoY). Promoter 18-month voluntary lock-in

2026-Q4

ICICI Bank credit facility of ₹15 Cr obtained

FY27

Revenue target ₹400-450 Cr. Ahmedabad full utilization targeted

FY27-28

Main board listing aspiration (NSE/BSE)

Management Commentary

“There is no entry barrier in this business... but exit is tough”

Management candidly admitting the commodity nature — moat is working capital management, not technology.

Q1 FY26 Concall, Jul 2025

“Our raw material is 100% cash purchase but we sell on credit”

Explaining structural negative cash flow — Hindalco demands cash, pharma clients pay in 45-70 days.

Q4 FY25 Concall, May 2025

“We are targeting ₹400-450 Cr topline for FY27”

FY27 guidance with combined facilities at full utilization.

Q4 FY26 Concall, Apr 2026

“Cash flow will turn positive over 18-20 months”

Addressing persistent analyst concerns about negative OCF.

Q2 FY26 Concall, Nov 2025

“No single client exceeds 3-4% of revenue... zero bad debts in 5 years”

100+ clients across 14 states with clean receivables history.

Q4 FY25 Concall, May 2025

“Combined ₹55-60 Cr/month at full capacity — Vasai ₹25-26 Cr plus Ahmedabad ₹25-30 Cr”

Existing infrastructure can support ₹650-700 Cr annualized revenue.

Q2 FY26 Concall, Nov 2025

“₹30-40 Cr of the ₹94 Cr receivables collected by April 20”

March receivables spike attributed to Iran-Israel-US conflict disrupting pharma export payments.

Q4 FY26 Concall, Apr 2026

“We are not looking at large pharma — their payment cycles are 90-150 days”

Deliberate client selection to maintain 45-60 day receivable cycle.

Q3 FY26 Concall, Feb 2026

6Financial Health Deep-Dive

P&L Snapshot

Metric	FY24 (Partial)	FY25	FY26
Revenue	₹40.8 Cr	₹133.8 Cr	₹258.2 Cr
EBITDA	₹2.7 Cr	₹15.3 Cr	₹29.8 Cr
EBITDA Margin	6.6%	11.4%	11.5%
PAT	₹1.37 Cr	₹9.65 Cr	₹19.84 Cr
PAT Margin	3.35%	7.21%	7.7%
EPS	₹1.46	₹7.53	₹14.08
ROCE	11.2%	25.2%	39.9%
Operating CF	(₹13.0 Cr)	(₹17.7 Cr)	(₹36.8 Cr)
Trade Receivables	₹7.2 Cr	₹33.8 Cr	₹94.3 Cr
Short-term Debt	₹4.5 Cr	₹17.8 Cr	₹44.4 Cr

Financial Commentary

The P&L looks excellent — revenue nearly doubling annually, margins expanding, ROCE at 39.9%. But the cash flow statement tells a different story. Operating cash flow has been negative every year: (₹13 Cr) → (₹17.7 Cr) → (₹36.8 Cr). The gap between PAT and OCF widened to ₹56.6 Cr in FY26. Trade receivables grew 13x while revenue grew 6.3x — receivable days are expanding. Short-term borrowings went from ₹4.5 Cr to ₹44.4 Cr to fund this gap. Every ₹100 of revenue growth requires ₹25-30 of incremental working capital, funded entirely by debt.

💰

Cash Flow vs PAT

FY26: PAT of ₹19.84 Cr vs negative OCF of (₹36.8 Cr) — a ₹56.6 Cr gap. Third consecutive year of negative OCF. Driven by ~₹60 Cr receivables increase in FY26 alone. Management targets positive OCF by mid-FY28 (18-20 months from Nov 2025). March 2026 receivables spike partially explained by geopolitical payment disruptions, with ₹30-40 Cr collected by April 20. But receivables growing 2x faster than revenue is a structural concern.

⚠️

Balance Sheet Flags

RED FLAGS: (1) Trade receivables ₹94.3 Cr growing 2x faster than revenue. (2) Short-term borrowings ₹44.4 Cr, up 10x in 2 years. (3) Negative OCF every year. (4) No aluminium hedging. POSITIVES: (1) ROCE 39.9%. (2) Zero bad debts in 5 years. (3) D/E manageable at 0.6-0.7x. (4) Asset-light — ₹5.5 Cr capex for ₹300+ Cr capacity. (5) Tier-1 banking (DBS, Tata Capital, ICICI).

Period-wise Analysis

FY24 (Partial)

₹40.8 Cr

Revenue

6.6%

EBITDA Margin

3.35%

PAT Margin

First year post-incorporation. Building operations from scratch. Low margins reflect startup phase.

Key Developments

→Company incorporated Sep 2023

→Listed on NSE Emerge May 31, 2024 at ₹32/share

→IPO raised ₹11 Cr for working capital

→Vasai facility operational with 65-70 pharma clients

FY25

₹133.8 Cr

Revenue

11.4%

EBITDA Margin

7.21%

PAT Margin

Breakout year — revenue tripled. Margins expanded as scale kicked in. Working capital intensity became visible.

Key Developments

→Revenue tripled to ₹133.8 Cr

→EBITDA margins jumped from 6.6% to 11.4%

→Vasai utilization reached 68-70%

→Rights issue of ~₹23 Cr completed

→Ahmedabad plant lease signed

Q1 FY26

₹52 Cr

Revenue

11.2%

EBITDA Margin

7.37%

PAT Margin

Strong quarter with 148% YoY growth. FY26 guidance of ₹190-260 Cr.

Key Developments

→Revenue ₹52 Cr (+148% YoY)

→QIP planning initiated

→Aluminium rate hike of 13-14% managed through inventory strategy

Q2 FY26

₹58 Cr

Revenue

11.43%

EBITDA Margin

7.56%

PAT Margin

Sequential growth continued. Ahmedabad targeting Dec operational start. FY26 guidance revised to ₹230-250 Cr.

Key Developments

→Revenue ₹58 Cr (+86% YoY)

→Ahmedabad operational by Dec

→Lamitube backward integration deferred

Q3 FY26

₹66.3 Cr

Revenue

11.89%

EBITDA Margin

8.04%

PAT Margin

Best quarter yet. Ahmedabad operational at 20-30%. FY26 target of ₹240 Cr on track.

Key Developments

→Revenue ₹66.3 Cr (+84% YoY) — quarterly record

→PAT margin hit 8.04% — best ever

→Vasai at 85-87% utilization

→Main board listing aspiration in 1.5-2 years

Q4 FY26

₹81.7 Cr

Revenue

11.5%

EBITDA Margin

7.7%

PAT Margin

Massive quarter — ₹81.7 Cr revenue. Receivables spiked to ₹94.3 Cr due to geopolitical disruption.

Key Developments

→Revenue ₹81.7 Cr (+79% YoY) — new record

→Full year FY26: ₹258.2 Cr (+93% YoY)

→Receivables spiked to ₹94.3 Cr — conflict impact

→ICICI Bank facility of ₹15 Cr obtained

→FY27 guidance: ₹400-450 Cr

→Promoter 18-month voluntary lock-in

7Governance, Risks & Monitoring Checklist

Governance & Compliance

Young company (Sep 2023 incorporation) with limited governance track record. Two-promoter structure with 73.14% combined holding. Regular quarterly concalls — management transparent about risks. Only 31 permanent employees. Promoter share sale in April 2026 mitigated by 18-month voluntary lock-in. Proactive business update issued to address investor concerns.

Key Risks

CriticalPersistently negative operating cash flow

OCF negative every year: (₹13 Cr) → (₹17.7 Cr) → (₹36.8 Cr). Growth funded entirely by debt and equity raises.

CriticalReceivables growing faster than revenue

Trade receivables 13x increase vs 6.3x revenue growth. Structural trend worsening year over year.

HighNo entry barriers / commodity business

Management admits no barriers. Backward-integrated competitors (PG Foils, MMP) have cost advantages.

HighAluminium price volatility — unhedged

No formal hedging. Geopolitical events can spike aluminium near all-time highs.

Medium-HighPO-to-PO model with zero visibility

No long-term contracts. FY27 target aspirational, not contract-backed.

MediumKey-person and thin team risk

31 employees and 2 promoters for ₹258 Cr operation. No succession plan.

MediumPromoter share sale optics

Insider selling during high-growth narrative despite voluntary lock-in follow-up.

MediumShort-term borrowing dependency

Borrowings surged 10x to ₹44.4 Cr. Interest rate sensitivity is material.

🚪

Exit Trigger

Exit if operating cash flow doesn't turn positive by FY28, if a major client defaults, if promoter stake drops below 65%, or if EBITDA margins fall below 10%

Quarterly Monitoring Checklist

Check these items every quarter to track this stock

Operating cash flow — must turn positive by mid-FY28

Trade receivable days — should stabilize at 60-65 days

Short-term borrowings trend — watch D/E ratio beyond 0.7x

Monthly revenue run-rate — needs ₹33-37 Cr/month for FY27 target

Ahmedabad utilization — 25-30% now, targeting 100% by FY27 end

Bad debt occurrence — first default is a major red flag

Aluminium prices vs EBITDA margins quarterly

Promoter shareholding changes post lock-in period

Backward integration progress (Lamitube — repeatedly deferred)

Main board listing application — signals governance maturity

Sources

1. Draft Red Herring Prospectus (DRHP) — GSM Foils Ltd

2. Annual Report FY 2024-25

3. Annual Report FY 2023-24

4. Q4 FY25 Concall Transcript (May 13, 2025)

5. Q1 FY26 Concall Transcript (Jul 25, 2025)

6. Q2 FY26 Concall Transcript (Nov 12, 2025)

7. Q3 FY26 Concall Transcript (Feb 2, 2026)

8. Q4 FY26 Concall Transcript (Apr 27, 2026)

9. Investor Presentation — Q1 FY26 (Jul 2025)

10. Investor Presentation — Q2 FY26 (Nov 2025)

11. Investor Presentation — Q3 FY26 (Feb 2026)

12. Investor Presentation — Q4 FY26 / Full Year FY26 (Apr 2026)

13. BSE Monthly Sales Update — April 2026

14. BSE Business Update — April 24, 2026

15. BSE Lock-in Update — April 25, 2026

The Verdict

Genuine growth story — revenue doubling annually, 39.9% ROCE, defensive pharma end market. But persistently negative operating cash flow and exploding receivables make this a high-risk bet on a low-moat, capital-hungry business.

Watch For

Operating cash flow turning positive (management targets mid-FY28), receivable days stabilizing below 65, Ahmedabad ramp to 50%+ utilization, bad debt occurrence.

₹258 Cr revenue with 39.9% ROCE but negative cash flow every year — brilliant scaling or a working capital time bomb?

Share your view in the comments below

Want the quick version?

See this stock summarised in 6 visual cards — business, moat, risks, and verdict at a glance.

View SME in 6 Cards

Disclaimer: For educational purposes only. Not SEBI-registered. Author may hold positions in stocks discussed. Not a buy/sell/hold recommendation. Do your own due diligence.

More Deep Dives

Airport Infrastructure

Anlon Technology Solutions Ltd

India's only Make in India fire truck manufacturer with 7 exclusive global OEM partnerships

Precision Engineering

Sunita Tools Ltd

From mould bases to 155mm artillery shells — India's boldest SME defence pivot

Precision Engineering

Apsis Aerocom Ltd

This Bangalore micro-cap makes precision parts for global aerospace & defence OEMs

Defence HVAC & Refrigeration

Shree Refrigerations Limited

India's only naval HVAC company with all 3 defence registrations — now entering data centre cooling

Cables & Wires

Prime Cable Industries Ltd

₹235 Cr revenue, ₹217 Cr order book — riding India's power infra boom

Transformers

Supreme Power Equipment Ltd

₹578 Cr order book, 20% EBITDA margins — this transformer maker is scaling 8x

Healthcare

Invicta Diagnostic Ltd

MMR's hub-and-spoke PET-CT diagnostic chain — 90% revenue growth with 32% EBITDA margins

Defence & Aerospace

Digilogic Systems Limited

India's defence ATE specialist with AS9100D certification — EBITDA margins doubled to 18.6% in FY25

Electrical Equipment

JD Cables Limited

From ₹41 Cr to ₹251 Cr in 2 years — 150% CAGR cable manufacturer now pivoting to ₹407 Cr EPC infrastructure

Railway Equipment

Kalyani Cast Tech Limited

IIT Madras founder builds India's import-substituting container maker — now eyeing ₹200 Cr wagon manufacturing bet

Healthcare

Nephro Care India Ltd

Nephrologist-founder builds East India's kidney care chain — now launching transplants and eyeing 300-clinic national footprint

Energy

Positron Energy Ltd

Three oil & gas veterans build India's asset-light gas aggregation platform — 39x revenue in 3 years with zero capex

Logistics

S J Logistics (India) Ltd

From freight broker to vessel operator — 3.4x revenue in 2 years with expanding margins

Aerospace & Defence

TechEra Engineering (India) Ltd

Building the tools that build India's fighter jets — from Tejas to C-295 to Rafale

Engineering Services

Telge Projects Limited

India's asset-light BIM engineering powerhouse with 33% EBITDA margins and 3.4x revenue growth in 2 years

Building Materials

Vigor Plast India Limited

The fittings-first PVC pipe brand earning 30% EBITDA margins where peers earn 12-15%

Food Processing

TBI Corn Limited

India's largest dry corn miller supplying ITC, Prataap Snacks & Balaji Wafers

Food Processing

MRP Agro Limited

Tikamgarh's dal mill story — ₹44 Cr → ₹104 Cr in one year, completely debt-free